Answers are grounded in this paper and cite their sources.
Capivasertib, a pan-AKT inhibitor, has shown promising efficacy in treating metastatic tumors harboring the AKT1 E17K mutation. However, its use is associated with notable adverse events, including hyperglycemia, which may impact treatment outcomes. This case describes a patient with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer and no prior history of diabetes who developed diabetic ketoacidosis (DKA) following capivasertib therapy.
No takes yet. Share an insight, caveat, or question.
Rodriguez et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: